Adult Dosing
Reduction of elevated IOP
- Recommended dose: 1 gtt in the conjunctival sac of the affected eye(s) qd in the evening
Notes:- Do not exceed recommended dose
- May be used concomitantly with other topical ophthalmic products to lower IOP. Administer each one at least 5 min apart, if more than one topical ophthalmic product is indicated
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Prostaglandin analogues may cause increased pigmentation of the iris, periorbital tissue such as eyelid, and eyelashes
- On discontinuation of therapy, pigmentation of the iris is likely to be permanent, while the eyelid and eyelash changes could be reversible in certain patients. Keep the patients informed of the possibility of increased pigmentation
- Pigmentation change may be due to an increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish
- Therapy may produce eyelash changes in the treated eye such as increased length, thickness, color, shape and number of lashes. These changes are usually reversible upon discontinuation of treatment
- Caution should be exercised in patients with active intraocular inflammation, as the inflammation may be exacerbated
- Macular edema, including cystoid macular edema, may occur during therapy
Cautions: Use cautiously in
- Aphakic patients
- Pseudophakic patients with a torn posterior lens capsule
- Risk factors for macular edema
Supplemental Patient Information
- Advise patients to promptly consult their physician if they develop a new ocular condition or any ocular reactions particularly conjunctivitis and eyelid reactions, have ocular surgery, or experience a sudden decrease in visual acuity during therapy
- Inform patients that the solution form one individual unit is to be used immediately after opening for administration, as the product does not contain a preservative
Pregnancy Category:C
Breastfeeding: Safety unknown. Excreted in breast milk of lactating rats; manufacturer advises caution.
